Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With Cancer: Economic Evaluation Within 5C Trial

Author:

Sahakyan Yeva1ORCID,Li Qixuan2ORCID,Alibhai Shabbir M.H.345ORCID,Puts Martine6ORCID,Yeretzian Shant T.7ORCID,Anwar Mohammed R.58ORCID,Brennenstuhl Sarah6ORCID,McLean Bianca9ORCID,Strohschein Fay1011ORCID,Tomlinson George258ORCID,Wills Aria6ORCID,Abrahamyan Lusine158ORCID

Affiliation:

1. Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Ontario, Canada

2. Biostatistics Department, University Health Network, University of Toronto, Toronto, Ontario, Canada

3. Department of Medicine, University Health Network, Toronto, Ontario, Canada

4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

5. Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

6. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada

7. Turpanjian College of Health Sciences, American University of Armenia, Yerevan, Armenia

8. Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada

9. Department of Medicine, Yale New Haven Hospital, New Haven, CT

10. Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada

11. Cancer Strategic Clinical Network, Alberta Health Services, Edmonton, Alberta, Canada

Abstract

PURPOSE Geriatric assessment (GA) is a guideline-recommended approach to optimize cancer management in older adults. We conducted a cost-utility analysis alongside the 5C randomized controlled trial to compare GA and management (GAM) plus usual care (UC) against UC alone in older adults with cancer. METHODS The economic evaluation, conducted from societal and health care payer perspectives, used a 12-month time horizon. The Canadian 5C study randomly assigned patients to receive GAM or UC. Quality-adjusted life-years (QALYs) were measured using the EuroQol five dimension-5L questionnaire and health care utilization using cost diaries and chart reviews. We evaluated the incremental net monetary benefit (INMB) for the full sample and preselected subgroups. RESULTS A total of 350 patients were included, of whom 173 received GAM and 177 UC. At 12 months, the average QALYs per patient were 0.728 and 0.751 for GAM and UC, respectively (ΔQALY, −0.023 [95% CI, −0.076 to 0.028]). Considering a societal perspective, the total average costs (in 2021 Canadian dollars) per patient were $46,739 and $45,177 for GAM and UC, respectively (ΔCost, $1,563 [95% CI, −$6,583 to $10,403]). At a cost-effectiveness threshold of $50,000/QALY, GAM was not cost-effective compared with UC (INMB, −$2,713 [95% CI, −$11,767 to $5,801]). The INMB was positive ($2,984 [95% CI, −$7,050 to $14,179]; probability of being cost-effective, 72%) for patients treated with curative intent, but remained negative for patients treated with palliative intent (INMB, −$9,909 [95% CI, −$24,436 to $4,153]). Findings were similar considering a health care payer perspective. CONCLUSION To our knowledge, this is the first cost-utility analysis of GAM in cancer. GAM was cost-effective for patients with cancer treated with curative but not with palliative intent. The study provides further considerations for future adoption of GAM in practice.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference40 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Canadian Cancer Statistics Advisory Committee in Collaboration With the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada: Canadian Cancer Statistics 2021. Toronto, ON, Canadian Cancer Society, 2021, pp 1-95

3. Comprehensive Geriatric Assessment as a Versatile Tool to Enhance the Care of the Older Person Diagnosed with Cancer

4. High-Cost Patients and Preventable Spending: A Population-Based Study

5. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3